Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 169

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 169
---
 from the process Kineta has undertaken to identify and evaluate strategic alternatives, the negotiation and consummation of any such transaction will require significant time on the part of the Company’s management, and the diversion of management’s attention may disrupt the Company’s business. The negotiation and consummation of any such transaction may also require more time or greater cash resources than Kineta anticipates and expose the Company to other operational and financial risks, including:

| • |     | inability to retain key employees of the Company or any merged business; |

| • |     | increased near-term and long-term expenditures; |

| • |     | exposure to unknown liabilities; |

| • |     | higher than expected acquisition or integration costs; |

| • |     | incurrence of substantial debt or dilutive issuances of equity securities to fund future operations; |

| • |     | write-downs of assets or incurrence of non-recurring, impairment or other charges; |

| • |     | increased amortization expenses; |

| • |     | difficulty and cost in combining the operations and personnel of any acquired business with its operations and personnel; |

| • |     | impairment of relationships with key suppliers or customers of any acquired business due to changes in management and ownership; and |

| • |     | possibility of future litigation. |

**98

Any of the foregoing risks could have a material adverse effect on Kineta’s business, financial condition and prospects.

Kineta may not fully realize the expected cost savings and/or operating efficiencies from its restructuring activities and its ability to consummate a strategic transaction depends on its ability to retain its employees required to consummate such transaction.

On February 29, 2024, Kineta announced that it had completed a review of its business, including the status of its programs, resources and capabilities. Following this review, Kineta implemented a significant corporate restructuring to substantially reduce expenses and preserve cash. The restructuring included a reduction in its workforce by approximately 64% and the termination of enrollment of new patients in its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. Patients currently enrolled in the trial were permitted to continue to participate. The Company made this decision, in part, because certain investors failed to fulfill their contractual obligation to fund and the second closing of the private placement for an aggregate purchase price of $22.5 million did not occur.

The Company believes these changes were needed to streamline its organization and reallocate its resources to better align with its current